This publication is intended as an educational resource for healthcare professionals. The review will
discuss the role of tolvaptan in the clinical management of autosomal dominant polycystic kidney
disease. Tolvaptan is currently the only approved pharmacological treatment which has been proven
to be effective in slowing the rate of kidney function decline in patients with autosomal dominant
polycystic kidney disease.1,2.
Independent commentary has been provided by Professor Carol Pollock, an academic nephrologist
and renal transplant physician with over 320 publications in basic research and clinical
medicine. Carol is a current Director of Kidney Health Australia. She is Chair of the NSW Cardiovascular
Research Network and the Research Advisory Committee of the Australian and New Zealand
Society of Nephrology, and Deputy Chair of the Australian Organ Tissue and Transplant Authority
Please login below to download this issue (PDF)